Francisco González Bobes was born and raised in Oviedo, Spain. He completed his undergraduate
studies at Universidad de Oviedo (Spain) in 1994 majoring both in Organic and Analytical
Chemistry. Francisco pursued doctoral studies at Instituto Universitario de Química
Organometálica (Universidad de Oviedo) obtaining his Ph.D. in 2003 under the guidance of
Professors José Barluenga and José Manuel González. His work focused on studying oxidation,
C-H functionalization, and C-C bond fragmentation reactions mediated by iodine-containing
reagents. In 2004, Francisco joined the laboratory of Professor Greg Fu at the Massachusetts
Institute of Technology as a Merck postdoctoral fellow. At MIT, he discovered that amino
alcohols and diamines could be used as ligands in asymmetric nickel-catalyzed cross-coupling
reactions of alkyl electrophiles bearing beta-hydrogens.
Francisco joined Bristol-Myers Squibb (BMS) in 2006 as a member of the Process Research &
Development department in New Brunswick, New Jersey (now Chemical & Synthetic
Development-CSD). Since then, he has applied his passion for chemistry to deliver innovative
solutions in the development of over 20 pharmaceutical candidates in areas such as immunooncology,
cardiovascular disease, immunoscience, central nervous system, and virology.
Currently, Francisco leads several projects in the BMS development portfolio, and is a technical
leader for CSD's interactions with several Chemical Research and Manufacturing Organizations.